Clostridium difficile colitis: pathogenesis and host defence.
Michael C Abt, Peter T McKenney, Eric G Pamer
https://pubmed.ncbi.nlm.nih.gov/27573580/Actively Recruiting
Led by Riverside University Health System Medical Center · Updated on 2025-11-10
176
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are evaluating whether oral vancomycin can prevent Clostridioides difficile infection C. diff in adults who are critically ill and at high risk due to their medical conditions and hospital stay. This trial also aims to understand the safety of vancomycin in this setting. The main questions are whether vancomycin lowers the infection rate and how carrier status of C. diff affects infection and clearance when vancomycin is used as primary prevention. Participants will be randomly assigned to receive either oral vancomycin 125 mg daily or a matching placebo while they are on systemic antibiotics, continuing up to five days after the last antibiotic dose, with the antibiotic treatment not exceeding 21 days. If discharged before completing the study medication, participants will continue taking it at home. Stool samples or rectal swabs will be collected to assess C. diff carrier status and changes in stool microbiome, including vancomycin-resistant Enterococcus VRE. During the study, participants will be monitored every three days until hospital discharge for adherence and side effects. After finishing the treatment, follow-up calls will be made to check for diarrhea or any adverse effects. The primary outcome is the rate of healthcare facility-onset C. diff infection, measured up to four months, along with secondary outcomes like VRE colonization, community-onset infections, time to infection in symptomatic patients, colonization at discharge, hospital stay length, and in-hospital mortality.
CONDITIONS
Enteral Vancomycin as Primary Prophylaxis Against Clostridioides Difficile Infection in Critically Ill Patients
S
Suman Thapamagar, MD
B
Brian Phan, PharmD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Riverside University Health System Medical Center
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Oral Vancomycin 125 mg (liquid) | Placebo oral (liquid) |
|---|---|---|
| What it is | A prophylactic antibiotic regimen using oral vancomycin (125 mg liquid) given daily to critically ill adults at high risk for CDI. | A matched liquid placebo taken orally, with no active antibiotic, intended to mirror the intervention regimen for comparison. |
| Primary use | Intended to prevent healthcare facility-onset Clostridioides difficile infection in critically ill patients receiving systemic antibiotics. | Serves as a comparator with no active preventive effect against CDI. |
| How it is given or performed | Administered daily as 125 mg oral liquid vancomycin. | Given daily as oral liquid placebo solution, matching vancomycin in appearance and schedule. |
| Evidence status | Evidence from recent systematic reviews and meta-analyses shows oral vancomycin can reduce CDI risk in selected high-risk patients, but widespread prophylactic use has not been adopted. Ongoing larger trials are expected to clarify benefit and risks. | No expected preventive effect against CDI; evidence supports that placebo reflects current practice without routine prophylaxis. |
| Important limitations | Potential for increased risk of vancomycin-resistant enterococci colonization, limited robust multicenter evidence for prophylactic use, unclear long-term safety and impact on microbiome, and uncertain applicability to broader ICU populations. | Does not provide active protection against CDI; may not reflect current prevention strategies combining infection control with risk assessment. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 screening and enrollment visit (in-person)
Duration - Up to 19 days depending on antibiotic duration (systemic antibiotic for at least 72 hours plus up to 5 days post-antibiotic)
Participants receive oral vancomycin 125 mg daily or a matching placebo daily during systemic antibiotic exposure and for up to five days after the last antibiotic dose.
Visits every 3 days until hospital discharge
Duration - Up to 4 months
Participants are monitored for clinical outcomes including incidence of Clostridioides difficile infection and vancomycin-resistant Enterococcus colonization after treatment ends.
Follow-up visits or assessments up to 4 months post-treatment
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Michael C Abt, Peter T McKenney, Eric G Pamer
https://pubmed.ncbi.nlm.nih.gov/27573580/Gayatri Vedantam, Andrew Clark, Michele Chu...
https://pubmed.ncbi.nlm.nih.gov/22555464/Alex Ganetsky, Jennifer H Han, Mitchell E Hughes...
https://pubmed.ncbi.nlm.nih.gov/30256954/Fernando Gil, Sebastián Lagos-Moraga, Paulina Calderón-Romero...
https://pubmed.ncbi.nlm.nih.gov/28254263/Ardeshir Rineh, Michael J Kelso, Fatma Vatansever...
https://pubmed.ncbi.nlm.nih.gov/24410618/Travis J Kochan, Matthew H Foley, Michelle S Shoshiev...
https://pubmed.ncbi.nlm.nih.gov/29760211/Steven W Johnson, Shannon V Brown, David H Priest
https://pubmed.ncbi.nlm.nih.gov/31560051/Neven Papic, Lorna Stemberger Maric, Adriana Vince
https://pubmed.ncbi.nlm.nih.gov/29323607/Adrián Martínez-Meléndez, Flora Cruz-López, Rayo Morfin-Otero...
https://pubmed.ncbi.nlm.nih.gov/35622552/Daniel Paredes-Sabja, Aimee Shen, Joseph A Sorg
https://pubmed.ncbi.nlm.nih.gov/24814671/Riverside University Health System Medical Center
Lead Sponsor